Takeda Pharmaceutical Company Limited
4502
Rank in Stocks
#378
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise... Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.
Share Price
$40.26
Market Cap
$64.06B
Change (1 day)
0.71%
Change (1 year)
42.44%
Country
JP
Trade Takeda Pharmaceutical Company Limited (4502)
Category
Healthcare
Earnings for Takeda Pharmaceutical Company Limited (4502)
Earnings in 2026 TTM: 0
According to Takeda Pharmaceutical Company Limited latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Takeda Pharmaceutical Company Limited from 2026 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
CH
|
|
| $1.76B | - |
IN
|
|
| - | - |
CN
|
